I am mindful of how life altering a diagnosis of cancer can be, not just for the patient, but all the loved ones in their life as well. Patients and families rightly deserve, and will always get the very best of us in intelligence and compassion, along with access to state of the art treatment which is continually improving long-term outcomes.
Work and Credentials:
Primary Location
Other Locations
Fauquier Office
Fairfax Office
Position
Medical Oncologist
Board Certification
Medical Oncology, Hematology, and Internal Medicine
Fellowship
Northwestern University Feinberg School of Medicine, Medical Oncology and Hematology
Internship
University of Michigan Health System
Residency
University of Michigan Health System
Medical School
Rutgers Robert Wood Johnson Medical School
College
Rutgers University
Special Interests
Malignant hematology (leukemia, lymphoma, myeloma), lung cancer, breast cancer & Clinical Trials
Mitul Gandhi, M.D. attended Rutgers University where he graduated Magna Cum Laude with a Bachelor of Arts in Molecular Biology and Biochemistry. He earned his medical degree from Rutgers Robert Wood Johnson Medical School where he received the Robert Wood Johnson Foundation Research Award among other honors. Dr. Gandhi then completed his residency and internship in Internal Medicine at University of Michigan Health System.
Dr. Gandhi joins Virginia Cancer Specialists after serving as Chief Fellow in the Medical Oncology and Hematology Fellowship program at Northwestern University Feinberg School of Medicine. During his time at Northwestern, Dr. Gandhi actively participated in clinical research, with a focus in high risk lymphoma. He has presented at major national meetings, won the American Society of Hematology’s Abstract Achievement Award in 2013, and has several publications including a recent article in Blood on double hit lymphomas. Dr. Gandhi is currently an Associate Member of both the American Society of Hematology and the American Society of Clinical Oncology.
In his spare time, Dr. Gandhi enjoys traveling with his wife, reading and writing, and spending time with family and friends.
Physician Video:
'
Practice Blog
February 14, 2024
Dr. Mitul Gandhi, Medical Oncologist at Virginia Cancer Specialists, Co-Authors Real-World Study Assessing Efficacy of Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndromes
Read MoreOctober 11, 2021
Virginia Cancer Specialists Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials
Read MoreMore Posts by Mitul Gandhi, MD
October 4, 2021
Virginia Cancer Specialists Opens New Office in Fauquier -- Expanding Access to Cancer Care, Research and Clinical Trials
Read MoreMarch 2, 2021
Mitul Gandhi, MD - Myeloma: Symptoms, Treatment, and the Role of Clinical Trials Event - March 25 2021
Read MoreJune 15, 2020
Dr. Mitul Gandhi, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve outcomes for patients with multiple myeloma
Read MoreMay 20, 2020
Practice Message Covid19 and Cancer: Cancer Doesn't Stop in a Pandemic
Read MorePhysician Publications
December 6, 2020
Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
Read MoreDecember 5, 2020
NHL Patients and Nurses in the US Prefer Subcutaneous Rituximab Injection Versus Intravenous Rituximab Infusion: A Real-World Study
Read MoreFebruary 15, 2016
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Read MoreMore Publications by Mitul Gandhi, MD
May 1, 2014
Pancreatitis in patients treated with Brentuximab Vedotin: A previously unrecognized serious adverse
Read MoreApril 22, 2014
Predicting benefit from imatinib. Are we close? Leukemia and Lymphoma.
Read MoreFebruary 13, 2014
Targeted treatment of head and neck squamous cell carcinoma: potential of lapatinib.
Read MoreNovember 15, 2013
Impact of Induction Regimen and Consolidative Stem Cell Transplantation in Double Hit Lymphoma (DHL)
Read MoreJanuary 7, 2013
Association of implantable defibrillator therapy risk with body mass index in systolic heart failure
Read MoreJanuary 1, 2013
Brentuximab Vedotin in Patients with Relapsed HIV-Related Lymphoma
Read More
